C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients

Clinical Biochemistry

Volumn 42, Issue 16-17, 2009, Pages 1713-1718

  Vivona, Nicoletta ^a   Bivona, Giulia ^b   Noto, Davide ^a   Sasso, Bruna Lo ^b   Cefalù, Angelo B ^a   Chiarello, Gaia ^b   Falletta, Angelo ^a   Ciaccio, Marcello ^b   Averna, Maurizio R ^a  

^a Department of Clinical Medicine and Emerging Diseases ^*  (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Coronary artery disease; Homocysteine; hs CRP; Risk factors; sCD40L

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; HOMOCYSTEINE;

ADULT; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

ADULT; C-REACTIVE PROTEIN; CD40 LIGAND; COHORT STUDIES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 70349782304     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.08.014     Document Type: Article

References (48)

1. Smith S.C., Greenland P., and Grundy S.M. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention. Circulation 101 (2000) 111-116
2. Eikelboom J.W., Lonn E., Genest Jr. J., Hankey G., and Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131 (1999) 363-375
3. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138 5 Pt 2 (1999) S419-S420
4. Kuller L.H., Tracy R.P., Shaten J., and Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144 6 (1996) 537-547
5. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Førde O.H., and Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24 (1995) 704-709
6. Graham I. Homocysteine in health and disease. Ann. Intern. Med. 131 (1999) 387-388
7. Kraus J.P. Biochemistry and molecular genetics of cystathionine beta-synthase deficiency. Eur. J. Pediatr. 157 suppl 2 (1998) S50-S53
8. Mudd S.H., Skovby F., Levy H.L., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet 37 (1985) 1-31
9. Ueland P.M., Refsum H., and Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis Jr. R.B. (Ed). Atherosclerotic cardiovascular disease, hemostasis, and endothelial function (1992), Marcel Dekker, New York 183-236
10. Verhoef P., and Stampfer M.J. Prospective studies of homocysteine and cardiovascular disease. Nutr. Rev. 53 (1995) 283-288
11. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci. 61 (1997) 1205-1215
12. Stamler J.S., and Slivka A. Biological chemistry of thiols in the vasculature and in vascular related disease. Nutr. Rev. 54 (1996) 1-30
13. Ridker P.M., Henneckens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
14. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
15. Ridker P.M., Buring J.E., Shih J., Matias M., and Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
16. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Ausburg Cohort Study 1984 to 1992. Circulation 99 (1999) 237-242
17. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med 331 7 (1994) 417-424
18. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 7 (1999) 855-860
19. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 9050 (1997) 462-466
20. Schonbeck U., and Libby P. CD40 signalling and plaque instability. Circ. Res. 89 (2001) 1092-1103
21. Blann A.D., Tan K.T., Tayebjee M.H., Davagnanam I., Moss M., and Lip G.Y. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb. Haemost. 93 (2005) 578-583
22. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348 12 (2003) 1104-1111
23. Ferrario M., Chiodini P., Chambless L.E., et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int. J. Epidemiol. 34 (2005) 413-421
24. Aukrust P., Müller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 6 (1999) 614-620
25. Blake G.J., Ostfeld R.J., Yucel E.K., et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler. Thromb. Vasc. Biol. 23 1 (2003) e11-e14
26. Verma S., Wang C.H., Li S.H., Lonn E., et al. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 182 2 (2005) 361-365
27. de Lemos J.A., Zirlik A., Schönbeck U., et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler. Thromb. Vasc. Biol. 25 10 (2005) 2192-2196
28. Alber H.F., Frick M., Suessenbacher A., et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-a randomized, placebo-controlled study. Am. Heart J. 151 1 (2006) 139
29. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., et al. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney Int. Suppl. 111 (2008) S60-S63
30. Azar R.R., Kassab R., Zoghbi A., et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am. Heart J. 151 2 (2006) 521.e1-521.e4
31. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 21 (2003) 2664-2669
32. Harding S.A., Sommerfield A.J., Sarma J., et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176 2 (2004) 321-325
33. Jinchuan Y., Zonggui W., Jinming C., Li L., and Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin. Chim. Acta. 339 1-2 (2004) 85-90
34. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351 25 (2004) 2599-2610
35. Arroyo-Espliguero R., Avanzas P., Quiles J., and Kaski J.C. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 204 1 (2009) 239-243
36. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347 (2002) 1557-1565
37. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
38. Ridker P.M. High-sensitive C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
39. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
40. Lip G.Y., Patel J.V., Hughes E., and Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation. Stroke (2007) 1229-1237
41. Omland T., Samuelsson A., Hartford M., et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch. Intern. Med. 160 12 (2000) 1834-1840
42. Stubbs P.J., Al-Obaidi M.K., Conroy R.M., Collinson P.O., Graham I.M., and Noble I.M. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 102 6 (2000) 605-610
43. Matetzky S., Freimark D., Ben-Ami S., et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch. Intern. Med. 163 16 (2003) 1933-1937
44. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337 4 (1997) 230-236
45. Fácila L., Nuñez J.E., VB G., et al. Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor?. Int. J. Cardiol. 100 (2005) 275-279
46. Foussas S.G., Zairis M.N., Makrygiannis S.S., et al. The impact of circulating total homocysteine levels on long-term cardiovascular mortality in patients with acute coronary syndrome. Int. J. Cardiol. 124 (2008) 312-318
47. Weber M., Rabenau B., Stanisch M., et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin. Chem. 52 (2006) 888-891
48. Weber M., Rabenau B., Stanisch M., et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb. Res. 120 (2007) 811-814